[go: up one dir, main page]

BR9802201A - Derivados 2-imidazolina 3 4-imidazol de metilfenil metoxifenil e aminofenil alguilsulfonamidas e seu uso no tratamento de incontinência urinária - Google Patents

Derivados 2-imidazolina 3 4-imidazol de metilfenil metoxifenil e aminofenil alguilsulfonamidas e seu uso no tratamento de incontinência urinária

Info

Publication number
BR9802201A
BR9802201A BR9802201A BR9802201A BR9802201A BR 9802201 A BR9802201 A BR 9802201A BR 9802201 A BR9802201 A BR 9802201A BR 9802201 A BR9802201 A BR 9802201A BR 9802201 A BR9802201 A BR 9802201A
Authority
BR
Brazil
Prior art keywords
alkylsulfonamides
aminophenyl
methoxyphenyl
methylphenyl
imidazole
Prior art date
Application number
BR9802201A
Other languages
English (en)
Other versions
BR9802201B1 (pt
Inventor
Richard Leo Cournoyer
Paul Francis Keitz
Counde O'yang
Dennis Mitsugu Yasuda
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26728313&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9802201(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR9802201A publication Critical patent/BR9802201A/pt
Publication of BR9802201B1 publication Critical patent/BR9802201B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/22—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/24—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • C07D233/50—Nitrogen atoms not forming part of a nitro radical with carbocyclic radicals directly attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/28—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BRPI9802201-6A 1997-06-23 1998-06-23 derivados de fenil- e aminofenil-alquilsulfonamidas e uréia, processo para sua preparação, composição farmacêutica, bem como aplicações farmacêuticas dos referidos derivados. BR9802201B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5047997P 1997-06-23 1997-06-23
US7597898P 1998-02-25 1998-02-25

Publications (2)

Publication Number Publication Date
BR9802201A true BR9802201A (pt) 1999-05-25
BR9802201B1 BR9802201B1 (pt) 2009-12-01

Family

ID=26728313

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9802201-6A BR9802201B1 (pt) 1997-06-23 1998-06-23 derivados de fenil- e aminofenil-alquilsulfonamidas e uréia, processo para sua preparação, composição farmacêutica, bem como aplicações farmacêuticas dos referidos derivados.

Country Status (30)

Country Link
US (2) US5952362A (pt)
EP (1) EP0887346B1 (pt)
JP (1) JP2977536B2 (pt)
KR (1) KR100608501B1 (pt)
CN (3) CN1262547C (pt)
AR (1) AR013005A1 (pt)
AT (1) ATE380793T1 (pt)
AU (1) AU713068C (pt)
BR (1) BR9802201B1 (pt)
CA (3) CA2418778C (pt)
CO (1) CO4940479A1 (pt)
CZ (1) CZ197498A3 (pt)
DE (1) DE69838829T2 (pt)
ES (1) ES2297870T3 (pt)
HR (1) HRP980353A2 (pt)
HU (1) HUP9801357A3 (pt)
ID (1) ID20463A (pt)
IL (2) IL124839A (pt)
MA (1) MA26515A1 (pt)
MY (1) MY128048A (pt)
NO (1) NO310868B1 (pt)
NZ (1) NZ330506A (pt)
PE (1) PE85999A1 (pt)
PL (1) PL198053B1 (pt)
RU (1) RU2218335C2 (pt)
SG (1) SG72827A1 (pt)
TR (1) TR199801197A2 (pt)
TW (1) TW517049B (pt)
UY (1) UY25057A1 (pt)
YU (1) YU26498A (pt)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407132B1 (en) * 1997-07-25 2002-06-18 James Black Foundation Limited Substituted imidazole derivatives and their use as histamine H3 receptor ligands
DE19824175A1 (de) * 1998-05-29 1999-12-02 Novartis Ag Amino-azol-Verbindungen
US20030073850A1 (en) * 1998-08-07 2003-04-17 Altenbach Robert J. 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use
US6503935B1 (en) * 1998-08-07 2003-01-07 Abbott Laboratories Imidazoles and related compounds as α1A agonists
US6395758B1 (en) * 1998-08-14 2002-05-28 Gpi Nil Holdings, Inc. Small molecule carbamates or ureas for vision and memory disorders
GB9910110D0 (en) * 1999-04-30 1999-06-30 Glaxo Group Ltd Chemical compounds
US20020183357A1 (en) * 2000-02-17 2002-12-05 Brioni Jorge D. Use of alpha- 1- alpha adrenoceptor agonists with alpha-1-Beta antagonism for the treatment of stress urinary incontinence
US6323231B1 (en) 2000-02-17 2001-11-27 Abbott Laboratories Use of α1A adrenoceptor agonists with α1B and α1D antagonism for the treatment of stress urinary incontinence
AU2001259536A1 (en) * 2000-05-10 2001-11-20 The Cleveland Clinic Foundation Model systems for neurodegenerative and cardiovascular disorders
AU2001286557A1 (en) * 2000-08-23 2002-03-04 Merck Frosst Canada And Co. Method of treating or preventing urinary incontinence using prostanoid ep1 receptor antagonists
EP1341529A2 (en) * 2000-11-10 2003-09-10 F. Hoffman-la Roche AG Hydrolytically unstable compositions
US20020169193A1 (en) * 2001-02-10 2002-11-14 Pascale Pouzet Alkylphenyliminoimidazolidine derivatives for treating urinary incontinence
DE10106214A1 (de) * 2001-02-10 2002-08-14 Boehringer Ingelheim Pharma Neue Alkyl-phenylimino-imidazolidin-Derivate zur Behandlung der Harninkontinenz
US20040170689A1 (en) * 2001-11-09 2004-09-02 Odink Debra Alida Stabilized formulations comprising hydrolytically unstable compositions
EP1333028A1 (en) * 2002-01-31 2003-08-06 Boehringer Ingelheim Pharma GmbH & Co.KG 2'-Halo-3',5'-dialkoxyphen-1'-yl-imino-2-imidazolidine derivatives and the use thereof for the treatment of urinary incontinence
US6703409B2 (en) 2002-01-31 2004-03-09 Boehringer Ingelheim Pharma Gmbh & Co Kg 2′-Halo-3′,5′-dialkoxyphen-1′-yl-imino-2-imidazolidine and the use thereof as a drug
PL373410A1 (en) * 2002-02-01 2005-08-22 F.Hoffman-La Roche Ag Substituted indoles as alpha-1 agonists
PL373322A1 (en) * 2002-04-23 2005-08-22 F.Hoffmann-La Roche Ag Imidazolinylmethyl aralkylsulfonamides
EP1660484B1 (en) * 2003-05-09 2008-08-27 F. Hoffmann-La Roche Ag Methyl indoles and methyl pyrrolopyridines as alpha-1 adrenergic agonists
US20060258986A1 (en) * 2005-02-11 2006-11-16 Hunter Ian W Controlled needle-free transport
PE20070341A1 (es) * 2005-07-29 2007-04-13 Wyeth Corp Derivados de pirrol como moduladores del receptor de progesterona
PE20070182A1 (es) * 2005-07-29 2007-03-06 Wyeth Corp Derivados cianopirrol-fenil amida como moduladores del receptor de progesterona
GB0519294D0 (en) * 2005-09-21 2005-11-02 Karobio Ab Compounds
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
MX2010000617A (es) 2007-07-17 2010-05-17 Plexxikon Inc Compuestos y metodos para modulacion de cinasa, e indicaciones de estos.
KR20100096262A (ko) * 2008-02-04 2010-09-01 에프. 호프만-라 로슈 아게 신규한 이미다졸리닐메틸 아릴 설폰아미드
CN101925579A (zh) * 2008-02-04 2010-12-22 霍夫曼-拉罗奇有限公司 新型的咪唑啉基甲基芳基磺酰胺
JP4168086B1 (ja) * 2008-04-16 2008-10-22 国立大学法人福井大学 イミダゾリン誘導体
EA022924B1 (ru) 2009-04-03 2016-03-31 Ф.Хоффманн-Ля Рош Аг ТВЁРДАЯ ФОРМА {3-[5-(4-ХЛОРФЕНИЛ)-1Н-ПИРРОЛО[2,3-b]ПИРИДИН-3-КАРБОНИЛ]-2,4-ДИФТОРФЕНИЛ}АМИДА ПРОПАН-1-СУЛЬФОНОВОЙ КИСЛОТЫ И ЕЁ ПРИМЕНЕНИЕ
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
NZ629615A (en) 2009-11-06 2016-01-29 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
SI2672967T1 (sl) 2011-02-07 2018-12-31 Plexxikon Inc. Spojine in postopki za kinazno modulacijo in indikacije zanjo
AR085279A1 (es) 2011-02-21 2013-09-18 Plexxikon Inc Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
TW201603707A (zh) * 2014-06-24 2016-02-01 陶氏農業科學公司 具有特定殺蟲效用之分子及與其相關之中間物、組成物和製程
CN106543077B (zh) * 2016-10-27 2019-08-23 西安交通大学 N,n’-双取代芳基硫脲衍生物及其合成方法和应用
CN106905181B (zh) * 2017-04-14 2018-10-09 上海海洋大学 一种立达霉代谢产物16的合成方法
CN108863818A (zh) * 2018-06-28 2018-11-23 江苏新瑞药业有限公司 一种对氨基间甲酚的合成方法
CN109651289B (zh) * 2018-12-18 2022-08-09 五邑大学 一种3-噻唑啉化合物及其合成方法和应用
EP3958851B1 (en) * 2019-04-23 2024-08-14 The Cleveland Clinic Foundation Allosteric activators of the alpha ia-adrenergic receptor
EP4048263A4 (en) * 2019-10-25 2023-11-15 Curasen Therapeutics, Inc. METHOD FOR TREATING NEURONOLOGICAL DISORDERS USING PARTIAL ALPHA 1A-AR AGONISTS
JP2023541375A (ja) * 2020-08-27 2023-10-02 キュラセン セラピューティクス インコーポレイテッド α１Ａ－アドレナリン受容体アゴニスト及び使用方法
WO2024166131A1 (en) 2023-02-09 2024-08-15 Satyarx Pharma Innovations Private Limited Heteroaryl compounds as pkmyt1 inhibitors
CN117447364A (zh) * 2023-10-17 2024-01-26 长沙贝塔医药科技有限公司 一种同位素标记合成对溴氰甲基苯磺酸酯-13c的方法及应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE135016C (pt) *
US2663732A (en) * 1950-04-29 1953-12-22 Eastman Kodak Co (alkysulfonamido) arylhydrazines
DE1151331B (de) * 1957-11-15 1963-07-11 Bayer Ag Verfahren zur Herstellung metallhaltiger Monoazofarbstoffe
AT241435B (de) * 1963-06-11 1965-07-26 Chemie Linz Ag Verfahren zur Herstellung von neuen Phenylalkanolaminderivaten und deren Salzen
ES323985A1 (es) * 1966-02-26 1966-12-16 Blade Pique Juan Procedimiento para la obtenciën de derivados del imidazol
GB1592649A (en) * 1976-12-20 1981-07-08 Wellcome Found Imidazoline derivatives and their use as pesticides
FR2373967A1 (fr) * 1976-12-20 1978-07-13 Wellcome Found Derives de l'imidazoline et leur emploi comme agents pesticides
CH632268A5 (de) * 1977-01-14 1982-09-30 Sandoz Ag Verfahren zur herstellung von neuen heterocyclylaminoderivaten.
IL55800A (en) * 1977-10-26 1982-05-31 Wellcome Found Imidazoline derivatives,their preparation and their use as arthropodicides
CA1138451A (en) * 1979-04-03 1982-12-28 Ikuo Ueda 2-imidazoline derivatives, process for the preparation thereof and the pharmaceutical composition of the same
US4343808A (en) * 1979-10-25 1982-08-10 The Dow Chemical Company Method of inhibiting sickling of sickle erythrocytes
EP0043659B1 (en) * 1980-07-09 1985-02-06 Beecham Group Plc Clonidine derivatives useful in the treatment of diarrhoea
FR2521140A1 (fr) * 1982-02-05 1983-08-12 Synthelabo Derives d'imidazolidine, leur preparation et leur application en therapeutique
FR2549049B1 (fr) * 1983-07-13 1986-06-20 Chauvin Blache Lab Nouvelles amidines, leur procede de preparation et leur application therapeutique
HU192986B (en) * 1984-05-23 1987-08-28 Egyt Gyogyszervegyeszeti Gyar Process for production of imidasodiline derivatives
US4665095A (en) * 1985-12-11 1987-05-12 Abbott Laboratories Use of 2-[(3,5-dihalo-4-aminobenzyl)]imidazolines to stimulate alpha-1 adrenergic receptors and to treat nasal congestion
US4956388A (en) * 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
DE3842798A1 (de) * 1988-12-20 1990-06-21 Hoechst Ag Imidazolinderivate enthaltende mittel zur wirtstiersystemischen bekaempfung von ektoparasiten sowie neue imidazolinderivate
PT95899A (pt) * 1989-11-17 1991-09-13 Glaxo Group Ltd Processo para a preparacao de derivados indole
US5360822A (en) * 1990-02-07 1994-11-01 Nippon Shinyaku Co. Ltd. Sulfonanilide derivatives and medicine
MX24595A (es) * 1990-06-29 1993-09-01 Sumitomo Chemical Co Derivados de fenilimidazol y procedimiento para supreparacion.
US5389650A (en) * 1991-09-30 1995-02-14 Merck Frosst Canada, Inc. (Azaarylmethoxy)indoles as inhibitors of leukotriene biosynthesis
AU3488693A (en) * 1992-02-13 1993-09-03 Merck Frosst Canada Inc. (Azaaromaticalkoxy)indoles as inhibitors of leukotriene biosynthesis
CA2145182C (en) * 1992-09-25 2001-09-18 Jonathan A. Bard Dna encoding human alpha 1 adrenergic receptors and uses thereof
WO1994008040A1 (en) * 1992-09-25 1994-04-14 Synaptic Pharmaceutical Corporation Dna encoding human alpha 1 adrenergic receptors and uses thereof
US5578611A (en) * 1992-11-13 1996-11-26 Synaptic Pharmaceutical Corporation Use of α-1C specific compounds to treat benign prostatic hyperplasia
US5403847A (en) * 1992-11-13 1995-04-04 Synaptic Pharmaceutical Corporation Use of α1C specific compounds to treat benign prostatic hyperlasia
HUT74386A (en) * 1993-11-15 1996-12-30 Schering Corp Phenyl-alkyl imidazoles as h3-receptor antagonists and pharmaceutical compositions containing them
US5576437A (en) * 1993-12-17 1996-11-19 The Procter & Gamble Company 7-(2-imidazolnylamino) quinoline compounds useful as alpha-2 adrenoceptor agonists
US5478858A (en) * 1993-12-17 1995-12-26 The Procter & Gamble Company 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists
US5616601A (en) * 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
EP0775134A4 (en) * 1994-08-04 1997-08-13 Synaptic Pharma Corp NEW BENZIMIDAZOLE DERIVATIVES
AU4176396A (en) * 1994-12-08 1996-06-26 Knoll Aktiengesellschaft Use of substituted phenylamidine and phenylguanidine compounds for the treatment of cerebral and cardiac ischaemia, convulsion and sickle cell anaemia
US5597823A (en) * 1995-01-27 1997-01-28 Abbott Laboratories Tricyclic substituted hexahydrobenz [e]isoindole alpha-1 adrenergic antagonists
DE19514579A1 (de) * 1995-04-20 1996-10-24 Boehringer Ingelheim Kg Verwendung von alpha¶1¶¶L¶-Agonisten zur Behandlung der Harninkontinenz
US5610174A (en) * 1995-06-02 1997-03-11 Synaptic Pharmaceutical Corporation Use of α1A -selective adrenoceptor agonists for the treatment of urinary incontinence
WO1996038143A1 (en) * 1995-06-02 1996-12-05 Synaptic Pharmaceutical Corporation The use of alpha-1c-selective adrenoceptor agonists for the treatment of urinary incontinence
US5677321A (en) * 1996-02-29 1997-10-14 Synaptic Pharmaceutical Corporation 5- and 6-(2-imidazolin-2-ylamino) and -(2-thiazolin-2-ylamino)-benzothiazoles as alpha-2 adrenergic ligands
JP2000506904A (ja) * 1996-05-16 2000-06-06 シナプティック・ファーマスーティカル・コーポレーション ジヒドロピリミジン類およびその使用

Also Published As

Publication number Publication date
AU7310298A (en) 1998-12-24
MA26515A1 (fr) 2004-12-20
NO310868B1 (no) 2001-09-10
CZ197498A3 (cs) 1999-01-13
EP0887346A2 (en) 1998-12-30
CO4940479A1 (es) 2000-07-24
NO982884D0 (no) 1998-06-19
KR100608501B1 (ko) 2006-12-19
CN1262547C (zh) 2006-07-05
PL198053B1 (pl) 2008-05-30
DE69838829D1 (de) 2008-01-24
CA2418778C (en) 2006-10-10
PE85999A1 (es) 1999-10-05
CN1515559A (zh) 2004-07-28
CA2418778A1 (en) 1998-12-23
CA2430623A1 (en) 1998-12-23
CN1203228A (zh) 1998-12-30
ES2297870T3 (es) 2008-05-01
NZ330506A (en) 1999-10-28
US6057349A (en) 2000-05-02
AR013005A1 (es) 2000-11-22
PL326959A1 (en) 1999-01-04
AU713068B2 (en) 1999-11-25
TR199801197A3 (tr) 1999-01-18
IL157745A0 (en) 2004-03-28
HUP9801357A3 (en) 2000-11-28
DE69838829T2 (de) 2008-12-24
HK1016985A1 (en) 1999-11-12
MY128048A (en) 2007-01-31
HRP980353A2 (en) 1999-04-30
CA2240136C (en) 2003-10-21
YU26498A (sh) 2002-03-18
ATE380793T1 (de) 2007-12-15
TW517049B (en) 2003-01-11
ID20463A (id) 1998-12-24
NO982884L (no) 1998-12-28
JPH1171353A (ja) 1999-03-16
JP2977536B2 (ja) 1999-11-15
EP0887346B1 (en) 2007-12-12
RU2218335C2 (ru) 2003-12-10
HU9801357D0 (en) 1998-08-28
IL124839A (en) 2004-03-28
US5952362A (en) 1999-09-14
SG72827A1 (en) 2000-05-23
HUP9801357A2 (hu) 1999-09-28
KR19990007204A (ko) 1999-01-25
CN1515562A (zh) 2004-07-28
TR199801197A2 (xx) 1999-01-18
IL124839A0 (en) 1999-01-26
UY25057A1 (es) 2001-01-31
AU713068C (en) 2004-03-11
CN1176910C (zh) 2004-11-24
EP0887346A3 (en) 1999-05-06
BR9802201B1 (pt) 2009-12-01
CA2240136A1 (en) 1998-12-23

Similar Documents

Publication Publication Date Title
BR9802201A (pt) Derivados 2-imidazolina 3 4-imidazol de metilfenil metoxifenil e aminofenil alguilsulfonamidas e seu uso no tratamento de incontinência urinária
DE69422102D1 (de) Wegwerfwindel in Höschenform
DE69529926D1 (de) Wegwerfwindel in Höschenform
TR199501305A2 (tr) Heterosiklik bilesikler ve bunlarin hazirlanmasi ve kullanimi
IL118247A0 (en) Use of R-enantiomer of N-propargyl-1-aminoindan and its salts
FI955360A0 (fi) Absorboivan kappaleen päällysarkki ja menetelmä sen valmistamiseksi
BR9711627A (pt) Derivados de cido propiÄnico e seu uso
PT1270565E (pt) Furano-2-sulfonamida 4-substituida e sua utilizacao na preparacao de derivados de sulfonilureia
EE04566B1 (et) Epotilooni derivaadid ja nende kasutamine meditsiinis
BR9406209A (pt) Derivados heterociclicos no tratamento de isquemia e doenças relacionadas
FI962649L (fi) Absorptiokappale absorboivassa tuotteessa
FI962650A7 (fi) Absorboivassa tuotteessa oleva absorboiva kappale
HUT77662A (hu) Kezelt fedőlappal ellátott pelenka
BR8901779A (pt) Absorvente higienico e metodo de aplicacao do mesmo
EP0793501A4 (en) IN VIVO ACTIVATION OF TUMOR SPECIFIC CYTOTOXIC T CELLS
BR9509700A (pt) Diidropirimidina e seus usos
ITMI992188A0 (it) Combinazione di sostanze attive dotate di proprieta' insetticide ed ac ariche
BR9704023A (pt) Derivados de n-(4-aril)-tiazol-2-ila-sulfonamida e seu uso
FI980546A0 (fi) Koppling foer att reglera impedansen i en differential aktivkomponent
FI964078A7 (fi) Ultraäänen käyttö paperinvalmistuksen yhteydessä
DE69517352D1 (de) Kosmetische Tensid-Präparate und deren Verwendung
IS5504A (is) Samsetning virk við meðhöndlun á getuleysi
FI953423A0 (fi) Temotsolomidin tehostaminen ihmisten kasvainsoluissa
BR9502691A (pt) Uso de ácido hialurônico e dispositivo protético
BR9703601A (pt) Derivados de triazina e seu uso

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/12/2009, OBSERVADAS AS CONDICOES LEGAIS.

B24H Lapse because of non-payment of annual fees (definitively: art 78 iv lpi)
B24F Patent annual fee: publication cancelled

Free format text: ANULADA A PUBLICACAO CODIGO 24.8 NA RPI NO 2259 DE 22/04/2014 POR TER SIDO INDEVIDA.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE AS 15A, 16A, 17A, 18A, 19A, 20A, 21A E 22A ANUIDADES.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2607 DE 22-12-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.